Tyra Biosciences (Tyra Biosciences) Debt-to-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences Debt-to-Asset?

Tyra Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.37 Mil. Tyra Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $6.12 Mil. Tyra Biosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $404.74 Mil. Tyra Biosciences's debt to asset for the quarter that ended in Mar. 2024 was 0.02.

Tyra Biosciences Debt-to-Asset Historical Data

The historical data trend for Tyra Biosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences Debt-to-Asset Chart

Tyra Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.48

0.01

0.03

Tyra Biosciences Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial												0.01	0.02	0.03	0.03	0.02

Competitive Comparison of Tyra Biosciences's Debt-to-Asset

For the Biotechnology subindustry, Tyra Biosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tyra Biosciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's Debt-to-Asset falls into.

Tyra Biosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tyra Biosciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.28	+	6.216)	/	225.857
	=	0.03

Tyra Biosciences's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.37	+	6.117)	/	404.741
	=	0.02

Tyra Biosciences (NAS:TYRA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tyra Biosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tyra Biosciences (Tyra Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2656 State Street, Carlsbad, CA, USA, 92008

Website

https://www.tyra.bio

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its lead product candidate is TYRA-300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Executives

Daniel Bensen	officer: Chief Operating Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Todd Harris	director, officer: Chief Executive Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Mva Investors, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alan Fuhrman	officer: Chief Financial Officer	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Ali D. Fawaz	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy	officer: General Counsel and Secretary	C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc	10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J More	director, 10 percent owner	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Alta Partners Nextgen Fund Ii, L.p.	10 percent owner	4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert L. Hudkins	officer: Chief Technology Officer	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Melissa Mccracken	director	C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008